ERNA MEXC RealStocks
Own real ERNA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 03:25:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Ernexa Therapeutics Inc. (ERNA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.84, with a market capitalization of $2.34M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.74 to $41.75. This page covers its latest market performance, valuation, price trends and company information.
$2.34M | |
$1.92 | |
$1.92 | |
$1.75 | |
$1.93 | |
23.68K | |
46.29K | |
-- | |
$41.75 | |
$1.74 | |
-- | |
-- |
Ernexa Therapeutics Inc. (ERNA) last closed at $1.84 as of 2026-11-13 00:56:00, down 4.18% ($0.08) from the previous close of $1.93.
During the latest regular trading session, ERNA traded between $1.75 and $1.92, with a volume of 23.68K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Ernexa Therapeutics Inc. (ERNA) moved from $2.02 to $1.84, representing a decline of 9.16% ($0.19).
The stock traded between $1.74 and $2.12 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 17.43 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.2%
ERNA is currently trading at $1.84, placing it 0.2% of the way from its 52-week low of $1.74 to its 52-week high of $41.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Ernexa Therapeutics Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Ernexa Therapeutics Inc. (ERNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ERNA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ERNA shares and USD.
ERNA Shares to USD
1.00 ERNA shares = 1.835 USD
Calculations are estimates based on the latest available price and are for reference only.